恶病质
医学
厌食症
免疫学
病理生理学
调解人
恶性肿瘤
单克隆抗体
单克隆
减肥
抗体
生物信息学
分解代谢
免疫疗法
转化研究
内科学
临床试验
治疗方法
瘦素
神经营养因子
受体
信号转导
自身免疫
肿瘤科
炎症
不利影响
癌症研究
作者
Cameron Oswalt,Jeffrey Crawford
标识
DOI:10.1146/annurev-med-042325-042958
摘要
Cachexia is a complex, multifactorial syndrome driven by anorexia and systemic inflammation, ultimately resulting in a catabolic state characterized by weight loss, decreased muscle mass, and impaired physical function. Many chronic comorbidities are implicated in the pathophysiology of cachexia, with malignancy being one of the most common. Although approved cachexia-directed therapies are limited to date, the growth differentiation factor 15 (GDF-15)-glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL) signaling axis has been identified as a primary mediator of cachexia and is an interesting pathway for cachexia-directed therapies and antibodies. Ponsegromab, a monoclonal antibody that is a highly selective and potent inhibitor of GDF-15, has resulted in improved body weight and other cachexia-related symptoms in patients with cancer. Other anti-GDF-15 and anti-GFRAL therapies are currently under investigation. Through the development of these treatments, many unexpected potential therapeutic applications have been identified, highlighting the broad, systemic impacts of cachexia. As research continues, it is imperative to focus on clear trial design and endpoints.
科研通智能强力驱动
Strongly Powered by AbleSci AI